4.6 Review

Dural repair with four spinal sealants: focused review of the manufacturers' inserts and the current literature

Journal

SPINE JOURNAL
Volume 10, Issue 12, Pages 1065-1068

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.spinee.2010.09.017

Keywords

Durotomy; Cerebrospinal fluid fistulas; Dural closure techniques; Sealants; Fibrin glue

Ask authors/readers for more resources

BACKGROUND CONTEXT: Deliberate or traumatic dural. fistulas are typically augmented by a sealant or fibrin glue to enhance the strength of dural closure. PURPOSE: Little is known about the risks and complications associated with two specific sealants and two specific fibrin glues used for dural closure. STUDY DESIGN/SETTING: Review of the manufacturers inserts and a focused review of the literature concerning the pros and cons for two sealants (DuraSeal [Confluent Surgical Inc., Waltham, MA, USA] and BioGlue [Cryolife, Kennesaw, GA, USA]) and two fibrin glues (EVICEL [Johnson and Johnson Wound Management, Ethic:on Inc., Somerville, NJ, USA] and Tisseel [fibrin sealant; Baxter International Inc., Westlake Village, CA, USA]) were assessed. PATIENT SAMPLE: A focused review of the literature using four different sealants or fibrin glues was performed. OUTCOME MEASURES: Documentation of persistent/recurrent postoperative cerebrospinal fluid fistulas was an end point for failure for the four different sealants and fibrin glues. METHODS: Manufacturers' inserts and a focused review of the literature concerning the relative safety and efficacy of two sealants (DuraSeal and BioGlue) and two fibrin glues (EVICEL and Tisseel) used to augment dural closure were assessed. RESULTS: Although DuraSeal is approved by the Federal Drug Administration (FDA) for intracranial and spinal application, two instances of paralysis are described in the literature. BioGlue is classified by the manufacturer as neurotoxic. EVICEL, one of the fibrin glues, appeared in just two animal studies, whereas Tisseel, the other fibrin glue, has been used in many large clinical series without adverse events. CONCLUSION: Despite the lack of FDA approval, Tisseel (fibrin glue) has seen wide adoption in off-label use. DuraSeal, which is FDA approved, was associated with two instances of paralysis. Alternatively, BioGlue was described as neurotoxic even by the manufacturer. (C) 2010 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available